Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA) will announce its first quarter 2022 financial results on May 5, 2022, at 8 a.m. ET. The company, a leader in genome editing focused on CRISPR technology, will discuss operational highlights during a conference call. U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will also be available. Post-call, a replay will be accessible on Intellia’s website.
- None.
- None.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on May 5, 2022, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatx.
Intellia Contacts:
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com
Lina Li
Director, Investor Relations and Corporate Communications
+1-857-706-1612
lina.li@intelliatx.com
FAQ
When will Intellia Therapeutics announce its Q1 2022 financial results?
How can I join the Intellia Therapeutics conference call?
Will there be a replay of the Q1 2022 financial results call for Intellia?
What technologies does Intellia Therapeutics focus on?
